| Data completeness |
| Number of cases | 10 920 | 16 922 | 20 639 | 25 757 | 30 158 | 30 329 |
| PS | 66% | 77% | 80% | 87% | 88% | 84% |
| Staging | 51% | 55% | 70% | 77% | 80% | 82% |
| Treatment | 66% | 72% | 79% | 82% | 89% | 89% |
| Process and outcomes |
| Confirmed histological diagnosis | 68% | 66% | 65% | 66.7% | 69.5% | 76.5% |
| Histology |
| NSCLC | 44.8% | 43.9% | 45.5% | 52.2% | 56% | 57% |
| SCLC | 10.3% | 10% | 9.6% | 10.3% | 10.5% | 10.9% |
| Mesothelioma | 3.7% | 3.5% | 4.2% | 4.4% | 5.0% | 5.5% |
| NSCLC NOS rate | – | 36% | 32% | 33.6% | 30% | 24% |
| Discussed at MDT? | 79% | 84.3% | 86.8% | 88.6% | 93.2% | 96.1% |
| Any anti-cancer treatment? | 45% | 50% | 52% | 54% | 58.9% | 58.5% |
| Overall surgical resection rate | 9% | 9.4% | 10.3% | 11.2% | 13.9% | 13.9% |
| NSCLC resection rate | 13.8% | 14.3% | 15.2% | 16% | 19% | 18.3% |
| SCLC chemotherapy rate | 57.7% | 61.7% | 64.5% | 63% | 66% | 65% |
| 1 year survival | 35.5% | 35.0% | 34.6% | 34.7% | 35.2% | 35.8% |